Andrea Sacchetto, Carlotta Liberale, Marina Silvestrini, Giulio Riva, Roberto Saetti
Department of Otorhinolaryngology, San Bortolo Hospital, Viale Ferdinando Rodolfi, 37, 36100 Vicenza, VI Italy.
Member of Young Confederation of European ORL-HNS, Y-CEORL-HNS, Gothenburg, Sweden.
J Maxillofac Oral Surg. 2025 Jun;24(3):664-673. doi: 10.1007/s12663-025-02472-w. Epub 2025 Feb 13.
Metastasising pleomorphic adenoma (MPA) is a rare malignant tumour that can affect multiple organs with a considerable time latency compared to primary pleomorphic adenoma (PA). To date, MPA and its clinical course, including survival and relapse rates, are still poorly understood.
We performed a systematic literature review following the PRISMA 2020 guidelines. The research was carried out using the PUBMED database and the following search terms: . The inclusion criteria for the final selection were: case reports or case series as study designs, availability of full text, and diseases specific to the parotid gland. Review articles, articles without full text, and studies on salivary glands other than the parotid gland were excluded.
A total of 908 papers were initially selected and 42 patients. The mean age at the diagnosis of MPA was 49.2 years (range 13-75 years). The average interval of onset of first metastasis was 15.7 years (range 1.4-45 years). The most common sites of metastasis were the bones (23.8%) and lungs (23.8%). In 31 patients (73.8%) a surgical treatment for complete removal of MPA was performed, while 10 patients withstood definitive or adjuvant radiotherapy. The follow up status was described only in 22 out of 40 papers where only 3 patients died from the neoplasm.
MPA of the parotid gland is a rare condition. The transformation of a PA to MPA is unpredictable. Because of the scarcity of data in the literature, the long-term behaviour of metastatic neoplasm is uncertain. However, we found that 5 out of 19 patients experienced disease relapse after treatment. Additionally, the average survival rate for individuals with MPA of the parotid gland is 64% after 5 years. The preferred course of treatment, if possible, is the surgical removal of the neoplasm.
转移性多形性腺瘤（MPA）是一种罕见的恶性肿瘤，与原发性多形性腺瘤（PA）相比，它可累及多个器官，且有相当长的时间潜伏期。迄今为止，MPA及其临床病程，包括生存率和复发率，仍知之甚少。
我们按照PRISMA 2020指南进行了系统的文献综述。研究使用PUBMED数据库及以下检索词： 。最终入选标准为：病例报告或病例系列作为研究设计、有全文、以及针对腮腺的特定疾病。综述文章、无全文的文章以及关于腮腺以外唾液腺的研究均被排除。
最初共筛选出908篇论文及42例患者。MPA诊断时的平均年龄为49.2岁（范围13 - 75岁）。首次转移发病的平均间隔时间为15.7年（范围1.4 - 45年）。最常见的转移部位是骨骼（23.8%）和肺部（23.8%）。31例患者（73.8%）接受了手术治疗以完全切除MPA，而10例患者接受了确定性或辅助性放疗。40篇论文中仅有22篇描述了随访情况，其中仅3例患者死于该肿瘤。
腮腺MPA是一种罕见疾病。PA向MPA的转变不可预测。由于文献数据稀缺，转移性肿瘤的长期行为尚不确定。然而，我们发现19例患者中有5例在治疗后出现疾病复发。此外，腮腺MPA患者5年后的平均生存率为64%。如果可能，首选的治疗方法是手术切除肿瘤。
